Impact of Renal Impairment on the Pharmacodynamic and Pharmacokinetic Profiles of Epaminurad, a Novel Uric Acid Transporter 1 Inhibitor. [PDF]
Park SY, Hwang JG, Cho SK, Park MK.
europepmc +1 more source
Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. [PDF]
Wu J, Di H, Zhang Y, Zeng X.
europepmc +1 more source
Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors for Uricosuria. [PDF]
Bae E.
europepmc +1 more source
A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics and Safety of Dotinurad in Healthy Chinese Adults. [PDF]
Liu Y +6 more
europepmc +1 more source
From Multidimensional Management to Mechanistic Insight: A Review of Interventions for Hyperuricemia. [PDF]
Sun Q, Yin L.
europepmc +1 more source
Colon-Specific Delivery of Probenecid Enhances Therapeutic Activity of the Uricosuric Agent Against Rat Colitis. [PDF]
Jeong Y, Kim J, Kang C, Jung Y.
europepmc +1 more source
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study. [PDF]
Jun JB +17 more
europepmc +1 more source
Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study. [PDF]
Osonoi T +7 more
europepmc +1 more source
Changes in urinary albumin levels with dotinurad oral administration in hyperuricemic patients with microalbuminuria: a post hoc analysis. [PDF]
Takahashi T +3 more
europepmc +1 more source
A practical approach to joint pain in primary care. [PDF]
Lim JWW +4 more
europepmc +1 more source

